Dear Editor

Mucosal leishmaniasis (ML) is a disease that can destroy cartilages, the pharynx and larynx, as well as bone structures of the face [@B1] . The treatment of ML is essentially based on the use of antimonial pentavalent. However, this drug has several adverse effects (AEs) and contraindications. Amphotericin B has been an alternative to antimonial pentavalent, mainly the liposomal formulation (L-AMB) [@B2] . However, the cost of the drug can be prohibitive to developing countries, and the ideal dose has not yet been established. Amphotericin B lipid complex (ABLC) is another lipid formulation of amphotericin B, with less nephrotoxicity than the deoxycholate formulation and is less expensive than L-AMB. As far as we know, this is the first report on a series of cases on the treatment of ML with ABLC. We report 13 cases of patients with ML treated with ABLC from a Brazilian cohort from January 2000 to July 2015.

Patients with confirmed ML older than 18 years and followed-up for at least 6 months were included in the cohort. Patients without confirmation of ML and refusal of treatment were excluded. The diagnosis of ML included the amplification of *Leishmania* spp. DNA in tissue samples by molecular techniques, isolation of parasites in cultures, or the finding of typical structures during the histological examination or in immunohistochemistry tests. Otorhinolaryngological evaluations were performed in all patients. Pentavalent antimonial was the first option of treatment. Lipid formulations were indicated after pentavalent antimonial failure, appearance of side effects or the presence of a contraindication for the pentavalent antimonial use. The choice of the lipid formulation of amphotericin B was a medical decision and in 13 cases ABLC (1--4 mg/kg/day to achieve a cumulative dose of 1,500 to 2,500 mg) was administered.

Cure, failure and recurrence episodes were previously defined [@B3] . AEs associated with the treatment of ML were analyzed during the hospitalization period. Acute kidney injury (AKI) was defined according to the AKIN criteria [@B4] .

The median age of the patients was 58 \[IQR 55-65\] years old and 53.8% of patients were men. Most patients presented symptoms for more than 5 years (65.4%). All species identified were *L. braziliensis* . Treatment of all patients with ML was performed in the hospital with a median hospitalization time of 25 \[IQR 19-28\] days. ABLC was associated with several infusion-related AEs ( [Table 1](#t1){ref-type="table"} ). The cure rate of the group that used ABLC was 46.1%, and 1 case considered previously cured has recurred. The dosage of ABLC varied from 1 to 4.5 mg/kg (average 2.6 mg/kg). The mean cumulative dose was 1,253 mg (planned cumulative dose of 1,500 to 2,500 mg).

Table 1Clinical and laboratorial findings of 13 patients with mucosal leishmaniasis.NSexAgeWeightSitePrevious treatmentInterruption due to side effectsPhebitisInfusion side effectsAKICrCl\* (mL/min)Electrolyte disturbanceMyelo- toxicityDosage (mg/kg/d)Cure1M5293Palate and pharynxNoYesYesSweat, nausea, chest painNo77.2NoYes3.0No2F7263Nasal septumNoYesYesChest painNo35YesNo1.7No3M5895Nasal septumYesNoYesFever, sweat, nauseaNo108.2YesNo1.1Yes4F5564Nasal septumYesYesNoChillsNo42.8NoNo3.1No5M6472Nasal septumYesYesNoNausea and vomitsNo71.8NoNo2.8No6M7144Palate, pharynx and larynxNoNoYes No60.2YesNo4.5Yes7F5345Nasal septumNoYesNoNausea and vomitsNo54.4YesNo2.0No8F5345Nasal septumNoNoYesNausea and vomits, chest painYes79.5YesNo2.1Yes9M5774Nasal septumYesNoNo No62.7NoNo2.0Yes10F6158Palate and pharynxYesYesNoFeverNo23.8NoNo4.0No11F6549Palate, pharynx and larynxYesNoNo No51.6NoNo3.1Yes12M5774Nasal septumYesNoNo No43.3YesNo2.0Yes13Male7662Nasal septum and pharynxYesNoYes No52.3NoNo2.4No[^2]

Data on ABLC in the treatment of ML have not been published in the literature, although this drug has been used since the 1990s for the treatment of visceral leishmaniasis [@B5] . The results showed a success rate limited to 46.1% (6/13) and a relapse rate of 7.7%. Other drugs have shown clinical cure rates between 71.0% and 77.0% of the cases [@B1] . Recurrence with the use of antimonial pentavalent is around 22% [@B1] . However, the daily recommended dose was low, not achieving the adequate cumulative dose. The treatment of ML is still far from the ideal because the best performing drugs for this condition have numerous AEs, and drugs that are safer to use have lower efficacy. ABLC presented a low rate of cure and several side effects, suggesting that the use of this drug is questionable.
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